tiprankstipranks
Olema Oncology presents updated results for palazestrant
PremiumThe FlyOlema Oncology presents updated results for palazestrant
1M ago
Olema Oncology announces FDA clearance of IND for OP-3136
Premium
The Fly
Olema Oncology announces FDA clearance of IND for OP-3136
1M ago
Olema Pharmaceuticals Secures Major Partnership and Funding
Premium
Company Announcements
Olema Pharmaceuticals Secures Major Partnership and Funding
2M ago
Olema Oncology presents preclinical data on anti-tumor activity for OP-3136
PremiumThe FlyOlema Oncology presents preclinical data on anti-tumor activity for OP-3136
3M ago
Olema Oncology to present multiple posters at EORTC-NCI-AACR
Premium
The Fly
Olema Oncology to present multiple posters at EORTC-NCI-AACR
3M ago
Olema Pharmaceuticals Advances Breast Cancer Treatment Trials
Premium
Company Announcements
Olema Pharmaceuticals Advances Breast Cancer Treatment Trials
4M ago
Olema Oncology price target raised to $30 from $21 at Oppenheimer
PremiumThe FlyOlema Oncology price target raised to $30 from $21 at Oppenheimer
8M ago
Olema Oncology announces new data on palazestrant with ribociclib
Premium
The Fly
Olema Oncology announces new data on palazestrant with ribociclib
8M ago
Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results
Premium
Company Announcements
Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100